Established in late 1999 Scientific/clinical resources Ethics committees Regulatory body TT - 2002.

Slides:

Advertisements

Similar presentations

Gilead’s Tech Transfer Partnerships and IP in India

Advertisements

Involving all health care providers in collaborative TB/HIV activities Eva Nathanson PPM subgroup meeting Cairo, Egypt, 3-5 June 2008.

HIV CENTER for Clinical and Behavioral Studies at NY State Psychiatric Institute and Columbia University Understanding of Informed Consent and Motivators.

Role of the HIV/AIDS community in science & regulatory advocacy Nikos Dedes European AIDS Treatment Group 22 July 2014, Melbourne.

Pox-Protein Public-Private Partnership (P5)

FRESENIUS KABI SOUTHERN AFRICAN EXPERIENCE

DHHS/NIH/NIAID/DAIDS 5 October 2006 HIV Vaccine Research: Ethical and Regulatory Issues NIH (DAIDS) Experience Alan Fix, MD, MS Chief, Vaccine Clinical.

Working Together to Improve Global Health

Presentation to the 2014 International AIDS Conference

Practical Ethical Issues in HIV Research in South Africa William M Pick Acting President Medical Research Council & Professor Emeritus University of the.

State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.

Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

David M. Margolis, MD Professor of Medicine Towards an HIV cure: medical, social and ethical challenges in research and testing.

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

OIC-SHPA & Vaccines Need Assessment in OIC Member Countries

OIC STRATEGIC HEALTH PROGRAMME OF ACTION, 2014 – 2023 TOWARDS SELF RELIANCE OF VACCINES IN THE OIC MEMBER COUNTRIES Jeddah 25 – 26 June st MEETING.

Working across sectors Building collaborative eco-systems Lars Sundstrom SARTRE.

Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.

AIDS Vaccine R&D (post-AIDSVAX®). R&D challenges Products in development Funding AIDS vaccine R&D Access and advocacy.

HIV Vaccine Clinical Trials: In Theory and on the Ground Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department of Medical Microbiology.

Translating vision and strategies into the real world: community perspective Lihle Dlamini (Treatment Action Campaign, South Africa)

Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.

DR CHIDI V NWENEKA EXECUTIVE DIRECTOR AFRICAN AIDS VACCINE PARTNERSHIP AAVP and the Promotion of HIV Vaccines in Africa: Supporting Career Development.

Bernard A Fox, PhD Immediate Past President and Chair, Executive Council Society for Immunotherapy of Cancer (SITC) Defining the Critical Hurdles in Cancer.

ART Program of the HIV Vaccine Trials Network Margaret Wecker, PhD Associate Director, Scientific Operations and Business Development.

The HCV vaccine: cooperation in the shadow of the pyramids Antonella Folgori.

Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)

An adult learning intervention to effect transformation towards a learning organisation: A critical discussion Presented by Patricia Southwood.

DoHDST. South African AIDS Vaccine Initiative (SAAVI)  Established in late1999 by the South African government.  Based at the Medical Research Council.

Bridging Gap in Global Innovation – From need to Access, Said Business School, University of Oxford 9-13 September 2007 Strategies for Managing Innovation.

The French National Agency for Research on Aids and Viral Hepatitis – Clinical Research Legislation: A French Experience Ingrid Callies Legal Counsel in.

HIV/AIDS communities and AIDS vaccine research AIDES / TRT-5 Tour Essor 14, rue Scandicci Pantin Cedex.

GAVI/Vaccine Fund Support to Improve Injection Safety On behalf of the Injection Safety sub-group.

Improving Access and Quality Use of Medicines in Palliative Care within National Drug Policy, Regulatory, and Funding Frameworks Debra Rowett, Tania Shelby-James,

Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,

International Partnership for Microbicides Tessa Mattholie, European Liaison Officer, Brussels.

Medicines Transparency Alliance27/10/ MeTA Ghana Augustina Koduah (Mrs) Country Coordinator.

11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.

The AIDS Vaccine Policy Agenda Holly J. Wong Vice President, Public Policy International AIDS Vaccine Initiative (IAVI) Vienna, Austria International AIDS.

Vaccinomics: social and science systems in transition Farah Huzair Innogen, The Open University.

SARPAM Southern African Regional Programme for Access to Medicines and Diagnostics Presentation to Botswana TRIPS and Access to Medicines workshop 26 March.

Enter Title of Presentation on Master Slide U.S. Department of Health and Human Services Office of the Assistant Secretary for Public Health Emergency.

World Health Organization "3 by 5" Target Treat 3 million by 2005.

HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.

International perspectives on human gene editing: South Africa KEYMANTHRI MOODLEY DIRECTOR & PROFESSOR CENTRE FOR MEDICAL ETHICS & LAW DEPARTMENT OF MEDICINE.

Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.

The Medical Research Council Presentation to the Portfolio Committee on Science and Technology March 16, 2005

1/28/2016 Prevention Research and Natioanl Aids Plans Geneva 1 Prevention Research and National AIDS Plans June 2005 Geneva, Switzerland Prof. Roy.

Where do we go from here? Entebbe, th Jan 2013 Analysts: Andrew Kambugu Jim Muller Facilitators: Alash’le Abimiku Bob O’Neil.

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

WHO Medicines Strategy Progress: Priorities: Dr Guitelle Baghdadi Essential Drugs and Medicines Policy World Health Organization November.

Adult AIDS Clinical Trials Group International Therapeutic Initiative.

Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

What Is Ethics Review. In Groups More than 33 million people today have HIV and risk contracting AIDS if they do not receive effective inhibitor medications.

Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.

Impact of immune-driven sequence variation in HIV- 1 subtype C Gag-protease on viral fitness and clinical outcome Thumbi Ndung’u, BVM, PhD HIV Pathogenesis.

Public Health FY 2014 Sources - $ million  Public Health Fund - $ million FY 2014 Uses - $ million  Personnel – $ million  Services/Supplies.

HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.

Vaccine Development, Innovations and Investments Oslo Malaria Conference, “Getting To Zero” Jean Stéphenne, Chairman and President GlaxoSmithKline Biologicals.

Prevention Science Gaps and the HIV/AIDS Pandemic Quarraisha Abdool Karim, PhD Head: CAPRISA Women and AIDS Pogramme Associate Professor in Epidemiology,

MEP Interest Group on Brain, Mind and Pain

Big Data Analyses: The Cancer Moonshot

The Medical Research Council

Ebola: Towards establishing a holistic approach to achieve effective management and control 1Muhammed Afolabi, 1Anna Roca, 1Kalifa Bojang, 2Egeruan Imoukhuede,

African AIDS Vaccine Program (AAVP)

An Advocacy-Research Partnership: A Successful Knowledge-Translation Platform? McAuliffe, E, DePinho, H., Clark, P, Sawyer, A, Shehu, D, Masanja, H, Kamwendo,

Paul Stoffels, MD Vice Chairman, Chief Scientific Officer, Johnson & Johnson.

Research programmes funded by organisations in Africa in 2015.

Presentation transcript:

Established in late 1999 Scientific/clinical resources Ethics committees Regulatory body TT

SAAVI aims to develop an affordable, effective and locally relevant preventative HIV vaccine for southern Africa

HIV genetic diversity C C C C C A A A A AG AG AG AE AE AEGG G J J H B B B B B B B D D D D D F F K K C C C C C C C C C C C C C. Williamson et al

Making the vaccine Testing the vaccine Ethical issues Advocacy & community Others TT Immunology assessment Human Animal

What do we expect from an HIV vaccine?

“Viral load” in HIV Amount of HIV 5% 90% Progress to AIDS in 5 years

Potential end-points of HIV- vaccine efficacy trials

TT SAAVI Challenges

Making the vaccine Testing the vaccine Ethical issues Advocacy & community Others TT Immunology assessment Human Animal

TT Supporters and Funds

TT Good vaccine candidates 2.HIV subtypes 3.Community involvement 4.Ethical studies 5.Access to product 6.Pricing 7.Technology transfer Appropriate Clinical Trials $30 million

TT Manufacturing 1.Product? 2.When? 3.What dose? 4.Manufacturing plant 5.Personnel 6.Dose price 7.Distribution capacity $350 million Clinical trials lot Bulk supply

TT Government 2.Medicines Control Council 3.Ethics committees 4.Medical aids 5.Life Insurance 6.Blood transfusion services 7.State Vaccine Institute Strategic national alliances

TT Strategic international alliances 1.NIH 2.HVTN 3.IAVI 4.AAVP 5.EU 6.Public / private

CONCLUSIONSCONCLUSIONS SAAVI has dynamic team Different to all other initiatives Committed to excellence Massive / maturing challenges Consolidate and expand TT